Home Monitoring: what can we expect in the future?
Tóm tắt
The Home Monitoring of implanted cardiac rhythm management devices developed by Biotronik (Berlin, Germany) is a new useful tool for monitoring patients. Home Monitoring provides access to technical and clinical data, allowing almost continuous patient surveillance. The implanted defibrillators and pacemakers transmit encrypted messages, which are automatically analyzed in the Home Monitoring Service Center and sent to the physician. The expected benefit of this kind of data transmission is an improvement in patient follow-up and early detection of changes in the rhythmologic state of the patient. However, these new tools raise several questions, which will require an answer in the nearest future. These questions focus on safety and economic aspects, and on the liability of the physician and the manufacturer. Technological improvement is also expected.
Tài liệu tham khảo
Cazeau S (2004) Le point sur la télésurveillance. Stimucoeur 32:163–164
Chun S (2002) Improved patient care in the US with home monitoring pacemakers (abstract). Europace 3 (Suppl A): A71
Fauchier L, Sadoul N, Kouakam C et al (2005) Potential cost savings by telemedecine-assisted long-term care of implantable cardioverter defibrillator recipients. PACE 28:S255–S259
Lamaison D, Motreff P, Jean F et al (2004) Place de la télémédecine en rythmologie et stimulation cardiaque. Arch Mal Cur 97:1160–1164
Lucas-Baloup I (2004) Télécardiologie: aspects médico-légaux. Stimucoeur 32:165–166
Theuns DAMJ, Res JCJ, Jordaens LJ (2003) Home Monitoring in ICD therapy: future perspectives. Europace 5:139–142
Toselli T, Regoli F, Pratola C et al (2004) Implantable cardioverter-defibrillator Home Monitoring technology. Ital Heart J 5(Suppl. 1):30S–31S
Sauberman RB, Hsu W (2004) Technical performance and clinical benefit of remote monitoring of ICDs (abstract). Europace 6 (Suppl 1):160
Wallbrück K, Stellbrink C, Santini M et al (2002) The value of permanent follow-up of implantable pacemakers–first results of a European trial. Biomed Tech 47(Suppl 1, Pt 2):950–953